Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19

Objective: The coronavirus disease 2019 (COVID-19) pandemic reached New York City in March 2020, leading to a state of emergency that affected many lives. Patients who contracted the disease presented with different phenotypes. Multiple reports have described the findings of computed tomography scan...

Full description

Bibliographic Details
Main Authors: Youmna Abdelghany, Kharisa Rachmasari, Sergio Alvarez-Mulett, Rochelle Wong, Kapil Rajwani
Format: Article
Language:English
Published: SAGE Publishing 2022-09-01
Series:SAGE Open Medicine
Online Access:https://doi.org/10.1177/20503121221124761
_version_ 1828412721194860544
author Youmna Abdelghany
Kharisa Rachmasari
Sergio Alvarez-Mulett
Rochelle Wong
Kapil Rajwani
author_facet Youmna Abdelghany
Kharisa Rachmasari
Sergio Alvarez-Mulett
Rochelle Wong
Kapil Rajwani
author_sort Youmna Abdelghany
collection DOAJ
description Objective: The coronavirus disease 2019 (COVID-19) pandemic reached New York City in March 2020, leading to a state of emergency that affected many lives. Patients who contracted the disease presented with different phenotypes. Multiple reports have described the findings of computed tomography scans of these patients, several with pneumothoraces, pneumomediastinum, and subcutaneous emphysema. Our aim was to describe the incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema related to COVID-19 found on radiologic imaging. Methods: A retrospective chart review was conducted of all confirmed COVID-19 patients admitted between early March and mid-May to two hospitals in New York City. Patient demographics, radiological imaging, and clinical courses were documented. Results: Between early March and mid-May, a total of 1866 patients were diagnosed with COVID-19 in the two hospitals included in the study, of which 386 were intubated. The majority of these patients were men (1090, 58.4%). The distribution of comorbidities included the following: hypertension (1006, 53.9%), diabetes (544, 29.6%), and underlying lung disease (376, 20.6%). Among the 386 intubated patients, 65 developed study-specific complications, for an overall incidence of 16.8%; 36 developed a pneumothorax, 2 developed pneumomediastinum, 1 had subcutaneous emphysema, and 26 had a combination of both. The mean time of invasive ventilation was 14 days (0–46, interquartile range = 6–19, median 11). The average of highest positive end expiratory pressure within 72 h of study complication was 11 (5–24) cmH 2 0. The average of the highest peak inspiratory pressure within 72 h of complication was 35.3 (17–52) cmH 2 O. In non-Intubated patients, 9/1480 had spontaneous pneumothorax, for an overall incidence of 0.61 %. Conclusion: Intubated patients with COVID-19 pneumonia are at high risk of pneumothorax, pneumomediastinum, and subcutaneous emphysema. These should be considered in differential diagnosis of shortness of breath or hypoxia in a patient with a new diagnosis of COVID-19 or worsening hemodynamics or respiratory failure in an intensive care unit setting.
first_indexed 2024-12-10T12:54:45Z
format Article
id doaj.art-040f6cd3fbe8463da9f4cd478ab84a55
institution Directory Open Access Journal
issn 2050-3121
language English
last_indexed 2024-12-10T12:54:45Z
publishDate 2022-09-01
publisher SAGE Publishing
record_format Article
series SAGE Open Medicine
spelling doaj.art-040f6cd3fbe8463da9f4cd478ab84a552022-12-22T01:48:08ZengSAGE PublishingSAGE Open Medicine2050-31212022-09-011010.1177/20503121221124761Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19Youmna Abdelghany0Kharisa Rachmasari1Sergio Alvarez-Mulett2Rochelle Wong3Kapil Rajwani4Department of Internal Medicine, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USADepartment of Internal Medicine, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USADepartment of Medicine, Weill Cornell Medical Center, New York, NY, USADepartment of Internal Medicine, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USADepartment of Internal Medicine, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, New York, NY, USAObjective: The coronavirus disease 2019 (COVID-19) pandemic reached New York City in March 2020, leading to a state of emergency that affected many lives. Patients who contracted the disease presented with different phenotypes. Multiple reports have described the findings of computed tomography scans of these patients, several with pneumothoraces, pneumomediastinum, and subcutaneous emphysema. Our aim was to describe the incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema related to COVID-19 found on radiologic imaging. Methods: A retrospective chart review was conducted of all confirmed COVID-19 patients admitted between early March and mid-May to two hospitals in New York City. Patient demographics, radiological imaging, and clinical courses were documented. Results: Between early March and mid-May, a total of 1866 patients were diagnosed with COVID-19 in the two hospitals included in the study, of which 386 were intubated. The majority of these patients were men (1090, 58.4%). The distribution of comorbidities included the following: hypertension (1006, 53.9%), diabetes (544, 29.6%), and underlying lung disease (376, 20.6%). Among the 386 intubated patients, 65 developed study-specific complications, for an overall incidence of 16.8%; 36 developed a pneumothorax, 2 developed pneumomediastinum, 1 had subcutaneous emphysema, and 26 had a combination of both. The mean time of invasive ventilation was 14 days (0–46, interquartile range = 6–19, median 11). The average of highest positive end expiratory pressure within 72 h of study complication was 11 (5–24) cmH 2 0. The average of the highest peak inspiratory pressure within 72 h of complication was 35.3 (17–52) cmH 2 O. In non-Intubated patients, 9/1480 had spontaneous pneumothorax, for an overall incidence of 0.61 %. Conclusion: Intubated patients with COVID-19 pneumonia are at high risk of pneumothorax, pneumomediastinum, and subcutaneous emphysema. These should be considered in differential diagnosis of shortness of breath or hypoxia in a patient with a new diagnosis of COVID-19 or worsening hemodynamics or respiratory failure in an intensive care unit setting.https://doi.org/10.1177/20503121221124761
spellingShingle Youmna Abdelghany
Kharisa Rachmasari
Sergio Alvarez-Mulett
Rochelle Wong
Kapil Rajwani
Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19
SAGE Open Medicine
title Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19
title_full Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19
title_fullStr Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19
title_full_unstemmed Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19
title_short Incidence and management of pneumothorax, pneumomediastinum, and subcutaneous emphysema in COVID-19
title_sort incidence and management of pneumothorax pneumomediastinum and subcutaneous emphysema in covid 19
url https://doi.org/10.1177/20503121221124761
work_keys_str_mv AT youmnaabdelghany incidenceandmanagementofpneumothoraxpneumomediastinumandsubcutaneousemphysemaincovid19
AT kharisarachmasari incidenceandmanagementofpneumothoraxpneumomediastinumandsubcutaneousemphysemaincovid19
AT sergioalvarezmulett incidenceandmanagementofpneumothoraxpneumomediastinumandsubcutaneousemphysemaincovid19
AT rochellewong incidenceandmanagementofpneumothoraxpneumomediastinumandsubcutaneousemphysemaincovid19
AT kapilrajwani incidenceandmanagementofpneumothoraxpneumomediastinumandsubcutaneousemphysemaincovid19